On 23 October 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma,” stock code: 02196) held its 2025 first extraordinary general meeting (EGM) in Shanghai. According to the polling, all resolutions on the agenda were duly passed.

The total number of issued shares as of the EGM record date was 2,670,429,325, with 2,639,554,073 shares entitled to vote. A total of 1,640 shareholders and authorized proxies attended in person or by proxy, representing 1,100,625,377 voting shares (about 41.6974% of total voting shares). Multiple shareholders and their associates who held shares and had material interests in certain resolutions abstained from voting based on regulatory requirements.

Five special resolutions were approved, including the 2025 A Share Option Scheme, the Management Measures for the Appraisal System, mandates to the board to deal with the A Share Option Scheme, and the 2025 H Share RSU Scheme with its mandate to the board. Ordinary resolutions included the grant of restricted share units (RSUs) to specific executive directors and senior managers, the Renewed Financial Services Agreement with Fosun Finance, and the Renewed Products/Services Mutual Supply Framework Agreement with Sinopharm.

The company’s PRC legal advisers verified that the EGM was convened legally and complied with applicable regulatory and internal requirements. BDO Limited, alongside legal advisers and shareholder representatives, supervised the vote counting. All approved resolutions take immediate effect in accordance with relevant laws and the articles of association of Fosun Pharma.